PLA2G7 Antikörper
-
- Target Alle PLA2G7 (Lp-PLA2) Antikörper anzeigen
- PLA2G7 (Lp-PLA2) (Lipoprotein-Associated phospholipase A2 (Lp-PLA2))
-
Reaktivität
- Human
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser PLA2G7 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
- Kreuzreaktivität
- Human, Maus
- Aufreinigung
- Protein G purified
- Immunogen
- Recombinant LP-PLA2 Protein
- Klon
- 2A1B6
- Isotyp
- IgG1, IgG1 kappa
- Top Product
- Discover our top product Lp-PLA2 Primärantikörper
-
anti-Lipoprotein-Associated phospholipase A2 (Lp-PLA2) (AA 301-441) antibody
Lp-PLA2 Reaktivität: Human, Maus, Ratte, Schwein, Kaninchen WB, ELISA, IF (cc), IF (p), IHC (p), IHC (fro) Wirt: Kaninchen Polyclonal unconjugated
anti-Lipoprotein-Associated phospholipase A2 (Lp-PLA2) (AA 200-228) antibodyLp-PLA2 Reaktivität: Human WB, FACS, IHC (p) Wirt: Kaninchen Polyclonal RB21322 unconjugated
anti-Lipoprotein-Associated phospholipase A2 (Lp-PLA2) (AA 22-441) antibodyLp-PLA2 Reaktivität: Human WB, ELISA, IHC, ICC Wirt: Maus Monoclonal 3E1G5 unconjugated
anti-Lipoprotein-Associated phospholipase A2 (Lp-PLA2) antibodyLp-PLA2 Reaktivität: Human WB, ELISA, IHC Wirt: Maus Monoclonal 2A1B6 unconjugated
anti-Lipoprotein-Associated phospholipase A2 (Lp-PLA2) (AA 49-441) antibodyLp-PLA2 Reaktivität: Human WB, ELISA, IHC Wirt: Kaninchen Polyclonal unconjugated
anti-Lipoprotein-Associated phospholipase A2 (Lp-PLA2) (AA 22-441) antibodyLp-PLA2 Reaktivität: Human WB, ELISA Wirt: Maus Monoclonal 3D12B11 unconjugated
anti-Lipoprotein-Associated phospholipase A2 (Lp-PLA2) (AA 22-441) antibodyLp-PLA2 Reaktivität: Human ELISA Wirt: Maus Monoclonal 5D1 unconjugated
anti-Lipoprotein-Associated phospholipase A2 (Lp-PLA2) (AA 22-441) antibodyLp-PLA2 Reaktivität: Human WB, IHC, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Lipoprotein-Associated phospholipase A2 (Lp-PLA2) (AA 22-444) antibodyLp-PLA2 Reaktivität: Hund WB, IHC, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Lipoprotein-Associated phospholipase A2 (Lp-PLA2) (AA 207-236), (Middle Region) antibodyLp-PLA2 Reaktivität: Human WB, FACS, IHC (p) Wirt: Kaninchen Polyclonal unconjugated
-
- Applikationshinweise
- Recommended dilution:WB:1:500-1:5000,IHC:1:50-1:500,
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4 - Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- -20 °C,-80 °C
- Informationen zur Lagerung
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
- Target
- PLA2G7 (Lp-PLA2) (Lipoprotein-Associated phospholipase A2 (Lp-PLA2))
- Andere Bezeichnung
- PLA2G7 (Lp-PLA2 Produkte)
- Synonyme
- LDL-PLA2 antikoerper, LP-PLA2 antikoerper, PAFAD antikoerper, PAFAH antikoerper, Lp-PLA2 antikoerper, PAF-AH antikoerper, R75400 antikoerper, zgc:77563 antikoerper, phospholipase A2 group VII antikoerper, phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) antikoerper, PLA2G7 antikoerper, Pla2g7 antikoerper, pla2g7 antikoerper
- Hintergrund
-
Background: Platelet-activating factor acetylhydrolase deficiency (PAFAD) : An enzymatic deficiency that results in exacerbated bodily response to inflammatory agents. It can be associated with several disease states including inflammatory gastrointestinal disorders, asthma and atopy. Asthmatic individuals with PAFAD may manifest aggravated respiratory symptoms.
Aliases: PLA2G7, PAFAH, LP-PLA2
- UniProt
- Q13093
- Pathways
- Peptide Hormone Metabolism
-
